<DOC>
	<DOCNO>NCT00111618</DOCNO>
	<brief_summary>The purpose trial confirm safe dose AS1404 , give docetaxel , see whether add AS1404 docetaxel together improve outcome treatment , compare docetaxel alone .</brief_summary>
	<brief_title>Study AS1404 With Docetaxel Patients With Hormone Refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description>The overall aim study determine safety , tolerability efficacy AS1404 combination docetaxel patient hormone refractory metastatic prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<criteria>Age equal , great 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy great equal 3 month Histopathologically confirm adenocarcinoma prostate Metastatic progressive androgenindependent prostate cancer previous chemotherapy treatment At least 4 week flutamide 6 week bicalutamide nilutamide Patients undergone surgical castration must continue treatment luteinizing hormonereleasing hormone ( LHRH ) agonist . In patient , reason , LHRH agonist discontinue prior entry study , reinstituted disease progression must document . Hematological biochemical index screen within follow range : An absolute neutrophil count great equal 1.5 x 10^9/L ; A platelet count great equal 100 x 10^9/L ; A hemoglobin level great equal 10 g/dL . Adequate hepatic renal function , define : Serum bilirubin less equal upper limit normal ( ULN ) ; SGOT and/or SGPT less equal 1.5 x ULN concomitant alkaline phosphatase less equal 2.5 x ULN ; Serum creatinine less equal 120 micromol/L creatinine clearance great equal 60 mL/min . Be willing able provide write informed consent , opinion Investigator , able comply study assessment followup Serum testosterone great 50 ng/mL ( chemically castrate patient ) Decreasing PSA level antiandrogen withdrawal Previous chemotherapy treatment prostate cancer Patients receive blood transfusion growth factor aid hematological recovery within two week schedule baseline visit Concurrent severe and/or uncontrolled comorbid medical condition within 2 week screen Previous exposure AS1404 vascular target agent Clinically significant cardiac arrhythmia know QTc prolongation ( interval &gt; 450 msec ) Evidence severe uncontrolled systemic disease , opinion Investigator , might interfere patient 's participation study A history alcoholism ; drug addiction ; psychiatric condition , , opinion Investigator , would impair patient 's ability comply study procedures A history hypersensitivity taxanes drug formulate polysorbate 80 Treatment follow medication within two week AS1404 administration expect need treatment study period : Medications know modulate serotonin ; Medications know affect QT interval ; Current treatment , expect need treatment period ketoconazole , erythromycin , troleandomycin , and/or cyclosporine . The use agent know induce , inhibit , metabolize cytochrome P4503A4 undertaken caution . Concurrent previous malignancy different tumor type within five year start study , except adequately treat nonmelanoma skin cancer Clinical radiological evidence central nervous system ( CNS ) metastases Symptomatic peripheral neuropathy great equal National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) grade II Evidence significant clinical disorder laboratory finding , opinion Investigator , compromise patient safety study participation Participation prostate cancer investigational drug study study drug subsequently obtain product license Any concurrent treatment prostate cancer ( exception palliative radiotherapy ) specify protocol , include use herbal remedy , ( e.g . saw palmetto )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>vascular disrupting agent</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>efficacy</keyword>
	<keyword>hormone refractory prostate cancer</keyword>
</DOC>